Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Haijun Yang, Ping Zhang, Junkuo Li, Yang Gao, Luyao Zhao, Jia Li, Mei Guo, Jingfang Zhang, Haimei Li, Fuqiang Wang & Yufen Yuan. (2020) Targeting PIN-1 Attenuates GCB DLBCL Cell Proliferation Through Inhibition of PI3K/AKT Signaling. OncoTargets and Therapy 13, pages 8593-8600.
Read now
Read now
Wenli Cui, Shutao Zheng, Zebing Liu, Weige Wang, Ying Cai, Rui Bi, Bing Cao & Xiaoyan Zhou. (2017) PIK3CA expression in diffuse large B cell lymphoma tissue and the effect of its knockdown in vitro. OncoTargets and Therapy 10, pages 2239-2247.
Read now
Read now
Articles from other publishers (7)
Xue Chen, Lin Jia, Xiuqun Zhang, Tong Zhang & Yulin Zhang. (2022) One arrow for two targets: potential co-treatment regimens for lymphoma and HIV. Blood Reviews 55, pages 100965.
Crossref
Crossref
Joanna C. Dawes & Anthony G. Uren. (2021) Forward and Reverse Genetics of B Cell Malignancies: From Insertional Mutagenesis to CRISPR-Cas. Frontiers in Immunology 12.
Crossref
Crossref
Hafidha Bentayeb, Marine Aitamer, Barbara Petit, Lydie Dubanet, Sabria Elderwish, Laurent Désaubry, Armand de Gramont, Eric Raymond, Agnès Olivrie, Julie Abraham, Marie-Odile Jauberteau & Danielle Troutaud. (2019) Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects. Journal of Experimental & Clinical Cancer Research 38:1.
Crossref
Crossref
P A Riedell & M R Bishop. (2017) Post-autologous transplant maintenance therapies in lymphoma: current state and future directions. Bone Marrow Transplantation 53:1, pages 11-21.
Crossref
Crossref
Rosalba Camicia, Hans C. Winkler & Paul O. Hassa. (2015) Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Molecular Cancer 14:1.
Crossref
Crossref
Hao-Hui Chen, Wei-Ting Huang, Li-Wei Yang & Chung-Wu Lin. (2015) The PTEN-AKT-mTOR/RICTOR Pathway in Nasal Natural Killer Cell Lymphoma Is Activated by miR-494-3p via PTEN But Inhibited by miR-142-3p via RICTOR. The American Journal of Pathology 185:5, pages 1487-1499.
Crossref
Crossref
Agata Majchrzak, Magdalena Witkowska & Piotr Smolewski. (2014) Inhibition of the PI3K/Akt/mTOR Signaling Pathway in Diffuse Large B-Cell Lymphoma: Current Knowledge and Clinical Significance. Molecules 19:9, pages 14304-14315.
Crossref
Crossref